18.Haynes, B., J. Murai, and J.M. Lee, Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev, 2018. 71: p. 1-7. 19.Sun, K., et al., ...
1.Bac Viet Le, Paulina Podszywałow-Bartnicka, Katarzyna Piwocka, and Tomasz Skorski, Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality, Cancers 2022, 14, 5795. 2.Quigley, D.; Alumkal, J.J.; Wyatt, A.W.; Kothari, V.; Foye, A.; Lloyd, P.; Aggar...
1.Bac Viet Le, Paulina Podszywałow-Bartnicka, Katarzyna Piwocka, and Tomasz Skorski, Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality, Cancers 2022, 14, 5795. 2.Quigley, D.; Alumkal, J.J.; Wyatt,A.W.; Kothari, V.; Foye, A.; Lloyd, P.; Aggarwa...
This effect is caused by the combination of PARP inhibitor-induced DNA double-strand break (DSB) formation and functional deficiency of homologous recombination (HR) repair, which is the main repair pathway for DNA damage. On the other hand, the clonal evolution in tumors as a tumor ...
[9].Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed Pharmacother. 2020;123:109661. doi:10.1016/j.biopha.2019.109661 ...
PARP inhibitor resistance: the underlying mechanisms and clinical implications Abstract Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi targeting poly (ADP-ribose) ...
Bradley Monk, MD, FACOG, FACS:Another concept I want to talk about is that with all this maintenance therapy, particularly PARP inhibitors, there’s a concern that the mechanism of resistance to a PARP inhibitor may translate into the mechanisms of resistance of future cycles of chemotherapy. ...
(Pancreatic Cancer Olaparib Ongoing) trial has demonstrated that the median progression-free survival was observably longer in the olaparib group than in the placebo group. However, PARP inhibitor resistance has partially precluded their use in clinical applications, and the major mechanism underlying ...
希望氟唑帕利这个由我国自主研发的“福星”,能照耀更多我国晚期卵巢癌患者,并给她们带来更好的生存获益。 卵巢癌是最致命的女性生殖系统恶性肿瘤。 在2022年,全球有超过20万女性死于卵巢癌[1],中国占到其中近六分之一[2]。 卵巢癌之恶,体现在三个70%。具体来说,70%卵巢癌发现即晚期、70%患者会在2年内复发...
[100]. PARPi have been shown to result in early activation of ATR/CHK1 pathway, and the combination of olaparib with ATR inhibitor ceralasertib synergistically suppressed growth in PDX models ofBRCA1/2-mutant HGSOC [101]. Importantly, the combination has demonstrated activity in the setting ...